SWOG clinical trial number
S0316
Barriers to Accrual to Clinical Trials in Older (>= 65 Years) Cancer Patients
Closed
Phase
Accrual
97%
Published
Abbreviated Title
Barriers to Accrual
Status Notes
Activated
08/01/2004
Closed
06/15/2008
Participants
Limited: Institutions Listed on the Title Page
Eligibility Criteria Expand/Collapse
Pts must have a dx of breast, lung, or colorectal Ca. (Effective 4/15/07, the lung and colorectal strata are closed). Pts must be seen at the participating clinics listed on the title page of the protocol. For each pt seen at the clinic who is eligible, it is expected that one of the following two action will occur w/in 24 hrs: a) the pt will be assessed, consented, and registered OR b) the pt will be logged as a "non-participant". Note: Pts w/ anal cancer are eligible. Pts must either be new to the inst, or a known pt w/ a new dx of Ca/ new stage of Ca. Pts must be ready to initiate systemic therapy of any type. Prior involvement in a clinical trial is allowed. Pts must be under consideration for tx of their ca w/ systemic therapy. Pts under consideration for srg or RT tx alone are not eligible. Pts must not have a current psychiatric dx that would interfere w/ ability to participate. Pts must be able to read and understand English. Pts must be willing to complete required forms. Reg must occur w/in 24 hours of the initial physican consult for determination of systemic tx options. If a consult occurs on a Friday, the pt must be registered the following Monday. Similarly, if the consult occurs the day before a holiday, the pts must be registered to the study the next buisness day. Pt must >= 18 yo. The principal investigator at each site must completed and submitted the Site PI Inititation Form.
Publication Information Expand/Collapse
2016
PMid: PMID26468994 | PMC number: PMC4824189
2014
Enhancing nurse contributions to SWOG clinical trials
PMid: PMID24559777 | PMC number: PMC3961058
2012
PMid: PMID22723506 | PMC number: PMC3448411
2009
The influence of older age on physician and patient decision-making regarding enrollment to breast cancer clinical trials